In vivo, ex vivo, and in vitro effects of L-NAME and L-arginine on the metabolism of theophylline in the rabbit

Drug Metabolism and Disposition

Volumn 25, Issue 2, 1997, Pages 191-195

  Barakat, Mouhsine ^b   El Kadi, Ayman O S ^b   Du Souich, Patrick ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLURIC ACID; 1,3 DIMETHYLURIC ACID; 3 METHYLXANTHINE; ARGININE; N(G) NITROARGININE METHYL ESTER; THEOPHYLLINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSFORMATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; AREA UNDER CURVE; ARGININE; BIOTRANSFORMATION; CELLS, CULTURED; ENZYME INHIBITORS; HALF-LIFE; LIVER; MALE; METABOLIC CLEARANCE RATE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RABBITS; THEOPHYLLINE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0031037654     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. 2 to nitric oxide and citrulline. Biochem. Biophys. Res. Commun. 187, 880-886 (1992).
2. B. Clement and F. Jung: N-Hydroxylation of the antiprotozoal drug pentamidine catalyzed by rabbit liver cytochrome P-450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amdoximes. Possible relationship to the biological oxidation of arginine to NG-hydroxyarginine, citrulline, and nitric oxide. Drug Metab. Dispos. 22, 486-497 (1994).
3. M. Delaforge, A. Piffeteau, J. L. Boucher, and A. Viger: Nitric oxide formation during the cytochrome P-450-dependent reductive metabolism of 18-nitro oxyandrostenedione. J. Pharmacol. Exp. Ther. 274, 634-640 (1995).
4. V. Lischke, R. Busse, and M. Hecker: Inhalation anesthetics inhibit the release of endothelium-derived hyperpolarizing factor in the rabbit carotid artery. Anesthesiology 83, 574-582 (1995).
5. P. C. Kuo and K. Y. Abe: Cytokine-mediated production of nitric oxide in isolated rat hepatocytes is dependent on cytochrome P-450III. FEBS Lett. 360, 10-14 (1995).
6. P. C. Kuo, K. Y. Abe, and D. C. Dafoe: Cytochrome P450IIIA activity and cytokine-mediated synthesis of nitric oxide. Surgery 118, 310-317 (1995).
7. S. Moncada, R. M. J. Palmer, and E. A. Higgs: The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 12, 365-372 (1988).
8. J. E. D. Abrams: A symposium: nitroglycerin therapy - contemporary perspective. Am. J. Cardiol. 60, 1H-48H (1987).
9. R. G. Kilbourn and O. W. Griffith: Overproduction of nitric oxide in cytokine-mediated and septic shock. J. Natl. Cancer Inst. 84, 827-831 (1992).
10. M. A. Sarkar and B. J. Jackson: Theophylline demethylations as probes for P4501A1 and P4501A2. Drug Metab. Dispos. 22, 827-834 (1994).
11. H. R. Ha, J. Chen, A. U. Freiburghaus, and F. Follath: Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br. J. Clin. Pharmacol. 39, 321-326 (1995).
12. Z. Y. Zhang and L. S. Kaminsky: Characterisation of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem. Pharmacol. 50, 205-211 (1995).
13. P. du Souich, B. Hoen, C. Saunier, D. Hartemann, A. Sautegeau, A. Cornette, N. Delorme, J. M. Polu, and P. Sadoul: Theophylline disposition in patients with cold with and without hypoxemia. Chest 95, 1028-1032 (1989).
14. P. Chiodera, R. Volpi, and V. Coiro: Inhibitory control of nitric oxide on the arginine-vasopressin and oxytocin response to hypoglycaemia in normal men. Neuroreport 5, 1822-1824 (1994).
15. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes. 1. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378 (1964).
16. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
17. P. O. Seglen: Preparation of isolated rat liver cells. Methods Cell Biol. 13, 29-83 (1976).
18. M. Gibaldi and D. Perrier: Multicompartmental models. In "Pharmacokinetics" (J. Swarbrick, ed.), pp. 45-112. Marcel Dekker, New York, 1982.
19. B. J. Winer: "Statistical Principles in Experimental Design," 2nd ed., pp. 149-257, McGraw-Hill, New York, 1971.
20. O. G. Khatsenko, S. S. Gross, A. B. Rifkind, and J. R. Vane: Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc. Natl. Acad. Sci. U.S.A. 90, 11147-11157 (1993).
21. P. R. Ortiz de Montellano and M. A. Correia: Inhibition of cytochrome P450 enzymes. In "Cytochrome P450. Structure, Mechanism, and Biochemistry" (P. R. Ortiz de Montellano, ed.), pp. 305-364. Plenum Press, New York, 1995.
22. M. R. Franklin: Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacol. Ther. 2, 227-245 (1977).
23. D. A. Peterson, D. C. Peterson, S. Archer, and E. K. Weir: The nonspecificity of specific nitric oxide synthase inhibitors. Biochem. Biophys. Res. Commun. 187, 797-801 (1992).
24. E. Brouillet, D. Roeda, H. Valette, C. Fuseau, M. C. Guyot, and C. Crouzel: In vivo metabolites of N-omega-nitro-L-arginine methyl ester: methanol and N-omega-nitro-L-arginine. Eur. J. Pharmacol. 293, 487-490 (1995).
25. K. Krejcy, S. Schwarzacher, and G. Raberger: Distribution and metabolism of NG-nitro-L-arginine and NG-nitro-L-arginine methylester in canine blood in vitro. Naunyn Schiedebergs Arch. Pharmacol. 347, 342-345 (1993).
26. K. A. White and M. A. Marletta: Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry 31, 6627-6631 (1992).
27. J. P. Renaud, J. L. Boucher, S. Vadon, M. Delaforge, and D. Mansuy: Particular ability of liver P450s3A to catalyze the oxidation of N omega-hydroxyarginine to citrulline and nitrogen oxides and occurrence in NO synthase of a sequence very similar to the heme-binding sequence in P450s. Biochem. Biophys. Res. Commun. 192, 53-60 (1993).
28. M. E. McManus, J. O. Miners, D. Gregor, I. Stupans, and D. J. Birkett: Theophylline metabolism by human, rabbit and rat liver microsomes and by purified forms of cytochrome P450. J. Pharm. Pharmacol. 40, 388-391 (1988).
29. F. P. Guengerich: Human cytochrome P450 enzymes. In "Cytochrome P450. Structure, Mechanism, and Biochemistry" (P. R. Ortiz de Montellano, ed.), pp. 473-535. Plenum Press, New York, 1995.
30. J. A. Lorente, L. Landin, R. de Pablo, E. Renes, and D. Liste: L-Arginine pathway in the sepsis syndrome. Crit. Care Med. 21, 1287-1295 (1993).
31. C. W. Wu, C. W. Chi, C. C. Chiu, H. S. Wu, W. Y. Liu, F. K. P'eng, and S. R. Wang: Can daily dietary arginine supplement affect the function and subpopulation of lymphocytes in patients with advanced gastric cancer? Digestion 54, 118-124 (1993).
32. J. Brittenden, K. G. Park, S. D. Heys, C. Ross, J. Ashby, A. K. Ah-See, and O. Eremin: L-Arginine stimulates host defenses in patients with breast cancer. Surgery 115, 205-212 (1994).